



REGISTERED OFFICE

GRANULES INDIA LTD., 2nd Floor, 3rd Block, My Home Hub,
Madhapur, Hyderabad - 500 081, Telangana, INDIA.
Tel: +91 40 30660000, Fax: +91 40 23115145, mail@granulesindia.com, www.granulesindia.com
CIN: L24110TG1991PLC012471

Dated September 12, 2019

To,
National Stock Exchange of India Limited
BSE Limited
Symbol: NSE: GRANULES; BSE: 532482

Sub: Receipt of Establishment Inspection Report (EIR) from US FDA -Reg.

Ref: Our letter dated 26th July 2019 under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Dear Sir,

Please be informed that, US FDA has issued Establishment Inspection Report (EIR) for Company's Bonthapally facility located at Hyderabad, Telangana, India.

This facility was inspected by US FDA in July 2019 and there was one (1) observation during the inspection. Bonthapally facility is one of the world's largest single site Paracetamol API manufacturing plant by volume. Along with Paracetamol APIs, the Company has established Metformin and Guaifenesin API manufacturing plants in the same facility.

This is for your information and dissemination to the members of the exchange.

Thanking You.

Yours faithfully,

For GRANULES INDIA LIMITED

T. Chaitanya

**CHAITANYA TUMMALA
(COMPANY SECRETARY &
COMPLIANCE OFFICER)**